Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

TRITON-PN: En undersøgelse til evaluering af effektiviteten og sikkerheden af Nucresiran hos patienter med arvelig transthyretin amyloidose med polyneuropati (TRITON-PN)

16. november 2026 opdateret af: Alnylam Pharmaceuticals

TRITON-PN: En fase 3, global, randomiseret, åben-label undersøgelse til evaluering af effektiviteten og sikkerheden af Nucresiran hos patienter med arvelig transthyretin-medieret amyloidose med polyneuropati (hATTR-PN)

The purpose of this study is to:

  • Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed
  • Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

125

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

      • Belgrano, Argentina, C1428AQK
        • Rekruttering
        • Clinical Trial Site
      • Rosario, Argentina, CP2000
        • Rekruttering
        • Clinical Trial Site
      • Darlinghurst, Australien, 2010
        • Rekruttering
        • Clinical Trial Site
      • Woolloongabba, Australien, 4102
        • Rekruttering
        • Clinical Trial Site
      • Ribeirão Preto, Brasilien, 14051-140
        • Rekruttering
        • Clinical Trial Site
      • Rio de Janeiro, Brasilien, 22640-100
        • Rekruttering
        • Clinical Trial Site
      • Rio de Janeiro, Brasilien, 22775-001
        • Rekruttering
        • Clinical Trial Site
      • Salvador, Brasilien, 40290-000
        • Rekruttering
        • Clinical Trial Site
      • São Paulo, Brasilien, 04038-002
        • Rekruttering
        • Clinical Trial Site
      • Vancouver, Canada, V5Z 1M9
        • Rekruttering
        • Clinical Trial Site
      • Égkomi, Cypern, 2371
        • Rekruttering
        • Clinical Trial Site
      • London, Det Forenede Kongerige, NW3 2QG
        • Rekruttering
        • Clinical Trial Site
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • Clinical Trial Site
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Rekruttering
        • Clinical Trial Site
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • Rekruttering
        • Clinical Trial Site
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02118
        • Rekruttering
        • Clinical Trial Site
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Rekruttering
        • Clinical Trial Site
    • New York
      • New York, New York, Forenede Stater, 10032
        • Rekruttering
        • Clinical Trial Site
      • New York, New York, Forenede Stater, 10016
        • Rekruttering
        • Clinical Trial Site
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27514
        • Rekruttering
        • Clinical Trial Site
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37232
        • Rekruttering
        • Clinical Trial Site
    • Texas
      • Dallas, Texas, Forenede Stater, 75246
        • Rekruttering
        • Clinical Trial Site
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • Clinical Trial Site
      • Créteil, Frankrig, 94000
        • Rekruttering
        • Clinical Trial Site
      • Le Kremlin-Bicêtre, Frankrig, 94270
        • Rekruttering
        • Clinical Trial Site
      • Marseille, Frankrig, 13005
        • Rekruttering
        • Clinical Trial Site
      • Athens, Grækenland, 115 28
        • Rekruttering
        • Clinical Trial Site
      • Heraklion, Grækenland, 715 00
        • Rekruttering
        • Clinical Trial Site
      • Dublin, Irland, D24 NR0A
        • Rekruttering
        • Clinical Trial Site
      • Florence, Italien, 50134
        • Rekruttering
        • Clinical Trial Site
      • Milan, Italien, 20133
        • Rekruttering
        • Clinical Trial Site
      • Padova, Italien, 35128
        • Rekruttering
        • Clinical Trial Site
      • Pavia, Italien, 27100
        • Rekruttering
        • Clinical Trial Site
      • Roma, Italien, 00168
        • Rekruttering
        • Clinical Trial Site
      • Bunkyo C, Japan, 113-8519
        • Rekruttering
        • Clinical Trial Site
      • Kumamoto, Japan, 860-8556
        • Rekruttering
        • Clinical Trial Site
      • Matsumoto-shi, Japan, 390-8621
        • Rekruttering
        • Clinical Trial Site
      • Suita, Japan, 565-0871
        • Rekruttering
        • Clinical Trial Site
      • Kuala Lumpur, Malaysia, 59100
        • Rekruttering
        • Clinical Trial Site
      • Guadalajara, Mexico, 44670
        • Rekruttering
        • Clinical Trial Site
      • Tlalpan, Mexico, 14080
        • Rekruttering
        • Clinical Trial Site
      • Lisbon, Portugal, 1649-035
        • Rekruttering
        • Clinical Trial Site
      • Porto, Portugal, 4099-001
        • Rekruttering
        • Clinical Trial Site
      • Bern, Schweiz, 3010
        • Rekruttering
        • Clinical Trial Site
      • Barcelona, Spanien, 08035
        • Rekruttering
        • Clinical Trial Site
      • Huelva, Spanien, 21005
        • Rekruttering
        • Clinical Trial Site
      • L'Hospitalet de Llobregat, Spanien, 8907
        • Rekruttering
        • Clinical Trial Site
      • Madrid, Spanien, 28040
        • Rekruttering
        • Clinical Trial Site
      • Palma de Mallorca, Spanien, 07198
        • Rekruttering
        • Clinical Trial Site
      • Stockholm, Sverige, 113 61
        • Rekruttering
        • Clinical Trial Site
      • Umeå, Sverige, 907 37
        • Rekruttering
        • Clinical Trial Site
      • Seoul, Sydkorea, 06351
        • Rekruttering
        • Clinical Trial Site
      • Seoul, Sydkorea, 05030
        • Rekruttering
        • Clinical Trial Site
      • Taipei, Taiwan, 10002
        • Rekruttering
        • Clinical Trial Site
      • Taipei, Taiwan, 112
        • Rekruttering
        • Clinical Trial Site
      • Taoyuan City, Taiwan, 33305
        • Rekruttering
        • Clinical Trial Site
      • Istanbul, Tyrkiet (Türkiye), 34093
        • Rekruttering
        • Clinical Trial Site
      • Izmir, Tyrkiet (Türkiye), 35330
        • Rekruttering
        • Clinical Trial Site
      • Berlin, Tyskland, 10117
        • Rekruttering
        • Clinical Trial Site
      • Heidelberg, Tyskland, 69120
        • Rekruttering
        • Clinical Trial Site
      • Münster, Tyskland, 48149
        • Rekruttering
        • Clinical Trial Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Has documented diagnosis of hATTR-PN
  • Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant
  • Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive)
  • Has a Karnofsky Performance Status (KPS) of ≥60%

Exclusion Criteria:

  • Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study
  • Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis
  • Has a New York Heart Association (NYHA) heart failure classification >2
  • Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 upper limit of normal (ULN)
  • Has total bilirubin >1.5 ULN
  • Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m^2
  • Has other known causes of sensorimotor or autonomic neuropathy

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Nucresiran 300 mg

Patients will be administered nucresiran 300 mg subcutaneously (SC) once every 6 months (q6M) during the Treatment Period and Treatment Extension Period

Nucresiran 300 mg administered SC q6M

Andre navne:
  • ALN-TTRSC04
Aktiv komparator: Vutrisiran 25 mg followed by Nucresiran 300 mg

Patients will be administered vutrisiran 25 mg SC every 3 months (q3M) during the Treatment Period followed by nucresiran 300 mg SC q6M during the Treatment Extension Period

Nucresiran 300 mg administered SC q6M

Andre navne:
  • ALN-TTRSC04

Vutrisiran 25 mg administered SC q3M

Andre navne:
  • ALN-TTRSC02
  • AMVUTTRA

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tidsramme: Baseline and Month 9

The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome.

Baseline and Month 9

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Procentvis reduktion i serum TTR-niveauer i Nucresiran-gruppen sammenlignet med in-studie Vutrisiran-gruppen gennem måned 9
Tidsramme: Op til måned 9
Op til måned 9
Procentvis reduktion i serum TTR-niveauer i Nucresiran-gruppen sammenlignet med den inden for studiet Vutrisiran-gruppen gennem måned 18
Tidsramme: Op til måned 18
Op til måned 18
Procentuel reduktion i serum TTR-niveauer i Nucresiran-gruppen sammenlignet med in-study Vutrisiran-gruppen ved uge 6
Tidsramme: Uge 6
Uge 6
Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tidsramme: Baseline and Month 9

The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome.

Baseline and Month 9
Change from Baseline in Modified Body Mass Index (mBMI) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tidsramme: Baseline and Month 9

The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome.

Baseline and Month 9
Change from Baseline in the mNIS+7 Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18

The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome.

Baseline and Month 18
Change from Baseline in Norfolk QoL-DN Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18

The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome.

Baseline and Month 18
Change from Baseline in mBMI Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18

The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome.

Baseline and Month 18
Change from Baseline in Rasch-built Overall Disability Scale (R-ODS) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18

The R-ODS is a patient-reported measure of level of disability on a scale of 0-48, with 0 being the worst and 48 the best (no limitations); scores are based on activities of daily living and social participation. An increase in R-ODS from baseline suggests improvement in disability, and a decrease from baseline suggests worsening of disability.

Baseline and Month 18
Change from Baseline in Timed 10-meter Walk Test (10-MWT) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18

The timed 10-MWT is a measure of ambulatory ability and measures the time (in seconds) that it takes a participant to walk 10 meters (gait speed). An increase in gait speed from baseline represents improvement, and a decrease from baseline represents worsening.

Baseline and Month 18

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Medical Director, Alnylam Pharmaceuticals

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. februar 2026

Primær færdiggørelse (Anslået)

27. december 2027

Studieafslutning (Anslået)

12. juni 2031

Datoer for studieregistrering

Først indsendt

29. oktober 2025

Først indsendt, der opfyldte QC-kriterier

29. oktober 2025

Først opslået (Faktiske)

31. oktober 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • ALN-TTRSC04-004
  • 2025-522544-40-00 (Ctis)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Phase 2-4 trials:

Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU.

Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more.

Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .